LifeMD (LFMD) AI Stock Analysis

• Market Cap: $624.90M
• Dividend Yield: N/A
• Average Volume (3M): 1.96M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.59
• Revenue Growth: 43.07%
• EPS Growth: 55.40%
• Country: US
• Employees: 304
• Sector: Healthcare
• Sector Strength: 42
• Industry: Medical - Pharmaceuticals
• EPS (TTM): 0.01
• Shares Outstanding: 45,447,605
• 10 Day Avg. Volume: 2,425,189
• 30 Day Avg. Volume: 1,958,269
• PEG Ratio: 0.04
• Price to Book (P/B): -8.80
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.68
• Enterprise Value/Market Cap: <0.01
• Enterprise Value/Revenue: <0.01
• Enterprise Value/Gross Profit: 0.03
• Enterprise Value/Ebitda: -0.22
• 1Y Price Target: $12.33
• Price Target Upside: -10.33% Downside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6

• Rating: 57 Neutral
• Price Target: $13.50 ▼(-1.82%Downside)

LifeMD's overall score is influenced most by its mixed financial performance, with strong revenue growth overshadowed by profitability and balance sheet concerns. The positive earnings call and strategic acquisition bolster its score but are secondary to financial challenges.

Positive Factors

Financial Performance

Positive operating cash flows with $34.4M in cash and $3.1M cash flows from operating activities during 1Q25 indicate financial strength.

Revenue Guidance

Management has raised 2025 total revenue guidance to $268-275M, including Telehealth revenue of $208-213M.

Subscriber Growth

Telehealth active subscriber base grew 22% YoY to 290,660 at the end of 1Q25, indicating strong growth momentum.

Negative Factors

Competition

Risks include lower than projected growth of telehealth revenue, inability to acquire and retain new patients, and higher than expected competition.

FDA Ruling Impact

The FDA ruling that Novo Nordisk's injectable semaglutide is no longer in shortage led to a significant decline in LFMD shares.

Patient Conversion Challenge

LFMD must convert its patients from compounded semaglutide to branded alternatives within 90 days, posing a challenge.

LifeMD Business Overview & Revenue Model

Company Description

LifeMD, Inc. operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for care across various indications, including concierge care, men's sexual health, dermatology, and others in the United States. The company provides ShapiroMD, a telehealth platform brand that offers access to virtual medical treatment, prescription medications, patented-doctor formulated OTC products, and an FDA approved medical device for male and female hair loss, and female specific topical compounded medications for hair loss; RexMD, a men's telehealth brand that offers virtual medical treatment from licensed providers for a variety of men's health needs; LifeMD Primary Care, a personalized subscription-based virtual primary care platform that provides patients with primary care, urgent care, and chronic care needs, as well as .offers a mobile first platform that incorporates virtual consultations and treatment, prescription medications, diagnostics, and imaging; Cleared, a telehealth brand that provides personalized treatments for allergy, asthma, and immunology; and Nava MD, a female-oriented tele-dermatology and skincare brand that offers virtual medical treatment from dermatologists and other providers. It also offers PDFSimpli, an online software-as-a-service platform that allows users to create, edit, convert, sign, and share PDF documents. LifeMD sells its products directly to consumers and through e-commerce platforms, as well as through third party partner channels. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was founded in 1994 and is headquartered in New York, New York.

How the Company Makes Money

LifeMD generates revenue by offering subscription-based telehealth services and selling prescription medications directly to consumers. The primary revenue streams include membership fees for its telehealth platform, fees for virtual medical consultations, and sales of prescription medications and wellness products. The company has established significant partnerships with healthcare providers and pharmacies, which facilitate the efficient delivery of its services and products. Additionally, LifeMD capitalizes on cross-selling opportunities by offering complementary health and wellness products to its existing customer base, thereby enhancing its revenue potential.

LifeMD Financial Statement Overview

Summary

LifeMD shows strong revenue growth but struggles with profitability and negative equity, raising concerns about financial stability despite improved cash flow management.

Income Statement

LifeMD's income statement reveals a mixed performance. While there is a strong revenue growth trajectory, as seen with a steady increase in total revenue from $37.3M in 2020 to $220.9M in TTM 2025, the company faces persistent challenges with profitability. The net income remains negative, indicating ongoing losses, despite improvements in gross profit margins and EBIT margins showing some signs of operational efficiency gains. Nevertheless, the company needs to address its profitability issues to improve its financial health.

Balance Sheet

The balance sheet reflects significant concerns, particularly with the negative stockholders' equity in TTM 2025, signaling potential financial distress. The debt-to-equity ratio is not calculable due to negative equity, but the presence of substantial liabilities compared to assets suggests leverage concerns. The equity ratio is also negative, indicating more liabilities than assets, which may hinder financial stability and growth prospects without corrective actions.

Cash Flow

The cash flow statement indicates a positive trend in operating cash flow, shifting from negative figures in earlier years to $15.4M in TTM 2025. However, free cash flow remains modest at $3.2M, reflecting heavy capital expenditures. The company shows improved cash flow management but needs to achieve consistent free cash flow growth to ensure long-term financial sustainability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	220.89M	212.45M	152.55M	119.03M	92.88M	37.29M
Gross Profit	203.16M	242.40M	133.65M	100.37M	74.88M	28.39M
EBITDA	2.62M	-6.65M	-8.21M	-39.61M	-53.95M	-57.48M
Net Income	-11.51M	-18.88M	-20.60M	-45.02M	-61.32M	-60.52M
Balance Sheet
Total Assets	73.61M	72.46M	58.48M	25.67M	49.92M	13.05M
Cash, Cash Equivalents and Short-Term Investments	34.39M	35.00M	33.15M	3.96M	41.33M	9.18M
Total Debt	25.10M	25.10M	18.93M	4.13M	1.85M	1.06M
Total Liabilities	74.01M	76.51M	52.91M	32.97M	24.10M	13.88M
Stockholders Equity	-2.33M	-5.49T	3.51M	-6.83M	26.85M	1.35M
Cash Flow
Free Cash Flow	3.17M	5.98M	86.95K	-35.83M	-36.49M	-12.53M
Operating Cash Flow	15.38M	17.51M	8.82M	-22.94M	-33.09M	-12.13M
Investing Cash Flow	-12.21M	-11.54M	-8.73M	-13.91M	-3.40M	-798.14K
Financing Cash Flow	-3.88M	-4.12M	29.10M	-528.20K	68.64M	21.00M

LifeMD Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 13.75
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LFMD, the sentiment is Positive. The current price of 13.75 is above the 20-day moving average (MA) of 13.13, above the 50-day MA of 10.30, and above the 200-day MA of 6.63, indicating a bullish trend. The MACD of 0.97 indicates Positive momentum. The RSI at 61.04 is Neutral, neither overbought nor oversold. The STOCH value of 32.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LFMD.

LifeMD Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LFMD	57 Neutral	$624.90M	―	301.60%	―	43.07%	55.40%
WBA	57 Neutral	$9.91B	―	-60.49%	8.73%	6.22%	-8.21%
OSUR	57 Neutral	$225.15M	25.27	-7.77%	―	-46.95%	-237.44%
PETS	53 Neutral	$67.96M	307.48	0.36%	―	-10.82%	―
Sector *	51 Neutral	$7.41B	0.36	-61.88%	2.33%	16.99%	1.69%
FHTX	49 Neutral	$269.79M	―	322.49%	―	-30.66%	36.48%
AVIR	47 Neutral	$295.25M	―	-30.47%	―	―	-22.66%

LifeMD Corporate Events

LifeMD Stockholders Approve Directors and Accounting Firm

On June 13, 2025, LifeMD, Inc. held its annual meeting of stockholders where a quorum was present. During this meeting, stockholders approved the election of seven directors to serve until the next annual meeting and ratified the selection of CBIZ CPAs, P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (LFMD) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on LifeMD stock, see the LFMD Stock Forecast page.

LifeMD Acquires Optimal Human Health MD Assets

On April 25, 2025, LifeMD acquired key assets from Optimal Human Health MD, a nationwide women’s health virtual care provider, marking its entry into the women’s health market. This strategic acquisition aims to address the significant unmet need for accessible, personalized, and high-quality care in women’s health, particularly in areas like menopause and osteoporosis. The acquisition aligns with LifeMD’s strategy to scale high-demand specialty care verticals, leveraging its national provider network and partnerships to deliver comprehensive virtual-first women’s health services.